Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for fatty liver disease in early trial

NCT ID NCT06104319

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single dose of the experimental drug GSK4532990 in 61 adults with NASH, a type of fatty liver disease. Researchers measured how the drug moves through the body and affects liver proteins, while also checking for safety. The goal is to see if the drug can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GSK4532990
What this could lead to
If successful, this could point toward a treatment for non-alcoholic steatohepatitis (NASH), a serious liver disease.
What could go wrong
This is an early-phase study with only 61 participants, so results may not confirm effectiveness or safety for wider use. The drug may not improve liver health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

61 people

The number who actually took part.

Started

Jan 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be 18 to 75 years of age. * Participant must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed for the study. * Participants who have proven diagnosis of NASH or suspected NASH based on defined study criteria. * Participants must meet predefined stable use requirements of concomitant medications based on study criteria. Exclusion Criteria: Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study: * Cirrhosis or current unstable liver or biliary disease. * Other causes of liver disease including, but not limited to, alcohol-related liver disease, autoimmune disorders. * Known weight loss of ≥5% within 3 months prior to Screening. * Weight reduction surgery or procedures within 2 years of Screening. * Any contraindication to undergoing liver biopsy. * Any contraindication to undergoing Magnetic Resonance Imaging or FibroScan®.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non - alcoholic steatohepatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-alcoholic fatty liver disease

Contacts and locations

Locations

  • GSK Investigational Site

    Chula Vista, California, 91911, United States

  • GSK Investigational Site

    Montclair, California, 91763, United States

  • GSK Investigational Site

    San Diego, California, 91911, United States

  • GSK Investigational Site

    San Diego, California, 91942, United States

  • GSK Investigational Site

    Brandon, Florida, 33511, United States

  • GSK Investigational Site

    Miami, Florida, 33155, United States

  • GSK Investigational Site

    Miami, Florida, 33173, United States

  • GSK Investigational Site

    Miami Lakes, Florida, 33014, United States

  • GSK Investigational Site

    Indianapolis, Indiana, 46202, United States

  • GSK Investigational Site

    El Dorado, Kansas, 67042, United States

  • GSK Investigational Site

    Marrero, Louisiana, 70072, United States

  • GSK Investigational Site

    Austin, Texas, 78745, United States

  • GSK Investigational Site

    San Antonio, Texas, 78215, United States

  • GSK Investigational Site

    San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.